Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
Publication Date: July 27, 2020
Last Updated: March 22, 2022
Diagnosis
All patients with cancer anticipating systemic anticancer therapy should be tested for HBV by three tests prior to, or at the beginning of, systemic anticancer therapy:
- hepatitis B surface antigen (HBsAg)
- hepatitis B core antibody (anti-HBc) total immunoglobulin (Ig) or IgG
- antibody to hepatitis B surface antigen (anti-HBs)
(EB, S, B)Note: Anticancer therapy should not be delayed for the results of these screening tests. Findings of chronic HBV (HBsAg-positive) or past HBV (HBsAg-negative and anti-HBc-positive with either negative or positive anti-HBs) infection require reactivation risk assessment.
7341
Title
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy
Authoring Organization
American Society of Clinical Oncology